Rujun Gong1, Zhihong Liu, Leishi Li. 1. Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
Abstract
OBJECTIVE: Glomerular microthrombosis (GMT) is not uncommon in lupus nephritis and has been associated with active renal injury and progressive kidney destruction. We undertook this study to determine whether genetic variations of hemostasis factors, such as plasminogen activator inhibitor 1 (PAI-1) and fibrinogen, affect the risk of GMT. METHODS: A cross-sectional cohort of 101 lupus nephritis patients with or without GMT was genotyped for PAI-1 -675 4G/5G and beta-fibrinogen (FGB) -455 G/A gene polymorphisms and analyzed. RESULTS: PAI-1 4G/4G homozygotes and FGB A allele carriers were both at increased risk for GMT. When the data were stratified for both gene polymorphisms, an epistatic effect was detected. The PAI-1 4G/4G genotype was found to predispose to GMT not equally in all lupus nephritis patients, but only in FGB A allele carriers. Likewise, the association between the FGB A allele and GMT was restricted to lupus nephritis patients homozygous for the PAI-1 4G allele. This epistatic effect was revalidated by the multifactor dimensionality reduction (MDR) analysis and further assessed by incorporating a variety of environmental and clinical factors into the MDR analysis. The most parsimonious model that had a cross-validation consistency of 100% included joint effects of PAI-1 and FGB gene polymorphisms and anticardiolipin antibody (aCL) status and yielded the best prediction of GMT, with 66.6% accuracy. CONCLUSION: Our findings suggest that risk of GMT in lupus nephritis is attributable, at least in part, to an epistatic effect of PAI-1 and FGB genes, likely via an interaction with environmental/clinical factors, such as aCL.
OBJECTIVE:Glomerular microthrombosis (GMT) is not uncommon in lupus nephritis and has been associated with active renal injury and progressive kidney destruction. We undertook this study to determine whether genetic variations of hemostasis factors, such as plasminogen activator inhibitor 1 (PAI-1) and fibrinogen, affect the risk of GMT. METHODS: A cross-sectional cohort of 101 lupus nephritispatients with or without GMT was genotyped for PAI-1 -675 4G/5G and beta-fibrinogen (FGB) -455 G/A gene polymorphisms and analyzed. RESULTS:PAI-1 4G/4G homozygotes and FGB A allele carriers were both at increased risk for GMT. When the data were stratified for both gene polymorphisms, an epistatic effect was detected. The PAI-1 4G/4G genotype was found to predispose to GMT not equally in all lupus nephritispatients, but only in FGB A allele carriers. Likewise, the association between the FGB A allele and GMT was restricted to lupus nephritispatients homozygous for the PAI-1 4G allele. This epistatic effect was revalidated by the multifactor dimensionality reduction (MDR) analysis and further assessed by incorporating a variety of environmental and clinical factors into the MDR analysis. The most parsimonious model that had a cross-validation consistency of 100% included joint effects of PAI-1 and FGB gene polymorphisms and anticardiolipin antibody (aCL) status and yielded the best prediction of GMT, with 66.6% accuracy. CONCLUSION: Our findings suggest that risk of GMT in lupus nephritis is attributable, at least in part, to an epistatic effect of PAI-1 and FGB genes, likely via an interaction with environmental/clinical factors, such as aCL.
Authors: Amit K Maiti; Xana Kim-Howard; Prasenjeet Motghare; Vandana Pradhan; Kek Heng Chua; Celi Sun; María Teresa Arango-Guerrero; Kanjaksha Ghosh; Timothy B Niewold; John B Harley; Juan-Manual Anaya; Loren L Looger; Swapan K Nath Journal: Hum Mol Genet Date: 2014-03-07 Impact factor: 6.150
Authors: Jennifer A Smith; Donna K Arnett; Reagan J Kelly; Jose M Ordovas; Yan V Sun; Paul N Hopkins; James E Hixson; Robert J Straka; James M Peacock; Sharon L R Kardia Journal: Eur J Hum Genet Date: 2008-01-23 Impact factor: 4.246
Authors: Marco Goeijenbier; Joost C M Meijers; Fatih Anfasa; Jeroen M Roose; Cornelia A M van de Weg; Kamran Bakhtiari; Heikki Henttonen; Antti Vaheri; Albert D M E Osterhaus; Eric C M van Gorp; Byron E E Martina Journal: Front Microbiol Date: 2015-03-24 Impact factor: 5.640
Authors: Sharon L R Kardia; Reagan J Kelly; Mehdi A Keddache; Bruce J Aronow; Gregory A Grabowski; Harvey S Hahn; Karen L Case; Lynne E Wagoner; Gerald W Dorn; Stephen B Liggett Journal: BMC Med Genet Date: 2008-10-23 Impact factor: 2.103
Authors: Sharon L R Kardia; Yan V Sun; Sara C Hamon; Ruth Ann Barkley; Eric Boerwinkle; Stephen T Turner Journal: BMC Med Genet Date: 2007-09-13 Impact factor: 2.103
Authors: Sharon Lr Kardia; M Todd Greene; Eric Boerwinkle; Stephen T Turner; Iftikhar J Kullo Journal: BMC Med Genomics Date: 2008-05-15 Impact factor: 3.063